APA (7th ed.) Citation

Wang, H., Jiang, S., Luo, H., Zhou, F., He, D., Ma, L., . . . Ye, D. Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): A randomized, phase 3 study. Nature Publishing Group.

Chicago Style (17th ed.) Citation

Wang, Hongkai, et al. Patient-reported Outcomes of Rezvilutamide Versus Bicalutamide in Combination with Androgen Deprivation Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients (CHART): A Randomized, Phase 3 Study. Nature Publishing Group.

MLA (9th ed.) Citation

Wang, Hongkai, et al. Patient-reported Outcomes of Rezvilutamide Versus Bicalutamide in Combination with Androgen Deprivation Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients (CHART): A Randomized, Phase 3 Study. Nature Publishing Group.